Market Research Future predicted that the global ventilator-associated pneumonia market is poised to reach the highest valuation with noteworthy CAGR during the forecast period, 2018-2023.
Ventilator-associated pneumonia is a type of pulmonary infection caused by patients on ventilation. Ventilator-associated pneumonia is mainly due to lung disease, neurological disorders, and trauma in severely ill people. The diagnosis of VAP requires aggressive monitoring associated with X-ray, bed, and microbiological examinations of respiratory secretions. Admission to growing ICs due to the increasing prevalence of respiratory diseases, an increasing number of IC beds, and the incidence of traumatic injuries provide a favorable context for market growth. Government following the objectives to enhance the healthcare capabilities with advanced equipment and modern infrastructure is predicted to uplift the growth of the global ventilator-associated pneumonia market.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/1377
Intensive care patients need help for breathing, and a large number of people suffer from diseases such as heart disease that require continuous monitoring by the IC team. Ventilator-associated pneumonia is common in patients with IC. This is an important cause of morbidity and mortality in intensive care. This disease is the result of the presence of infected pathogenic secretions in the lungs. The long-term use of intensive care ventilators promotes the growth of this market. The increase in nosocomial infections is another factor that contributes to the growth of this market. Prevention of ventilator-associated pneumonia is important to protect the health of patients with life-threatening diseases.
Market Segmentation
The global market for ventilator-related pneumonia is segmented based on diagnosis, mode of treatment, and end-user.
The ventilation-related pneumonia market is classified by diagnosis into the following categories: clinical examination, radiological examination, microbiological analysis, and others.
The mode of treatment segment is segmented into home care, hospital care, and others.
Based on the end-user, the global market is segmented into hospitals and clinics, outpatient care centers, research centers, and emergency medical services (EMS).
Regional Insights
The Americas is the leading regional market for ventilation-associated pneumonia (VAP), whose growth attributed to increased smoking prevalence, leading to lung disease, a large number of patients with chronic heart disease, and the demand for ventilators. The market is constantly growing in Europe due to the high demand, rising healthcare costs, and medical devices in hospitals.
The Asia Pacific region is expected to become the fastest-growing market due to increased environmental pollution, high occurrence of asthma, and chronic obstructive pulmonary disease, and a large patient population. In addition, awareness of the prevention of nosocomial infections, pneumonia, and the quality control measures taken by hospitals to combat nosocomial infections stimulate the growth of this market.
The aging population and the incidence of infectious diseases also contribute to the growth of this market in the Asia Pacific. On the other hand, the Middle East and the African region are expected to experience limited but steady market growth.
Market Players
The key players actively participating in the growth of the global ventilator-associated pneumonia market are Adenium Biotech ApS, Nabriva Therapeutics AG, Merck & Co., Inc, AstraZeneca, and MedImmune. The Industry players are majorly focusing on acquiring new technologies to ease the process and bring effective methodologies dedicated to treatment.
Recent News
- According to the study presented by the US specialty chemicals company, Cumberland unveiled the superiority Of Vibativ® Over Vancomycin for selective patients suffering from bacterial pneumonia. Vibativ® (telavancin) is an FDA approved, patented anti-infective treatment of bacterial infections comprising ventilator-associated bacterial pneumonia and hospital-acquired. It discourses a range of gram-positive bacterial pathogens, comprising those that are considered multidrug-resistant and intricate-to-treat.
Browse Premium Research Report with Tables and Figures @ https://www.marketresearchfuture.com/reports/ventilator-associated-pneumonia-vap-market-1377
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
